2 completed, 2 not yet recruiting, 1 recruiting. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Not yet recruiting 2, Recruiting 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Ectodermal Dysplasia: new trials by email Literature Review of Ectodermal Dysplasia trials Research Report on Ectodermal Dysplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epidermal Growth Factor Receptor Inhibition for Keratinopathies Erlotinib - Epidermolytic Ichthyosis, Palmoplantar Keratoderma | Phase 1 / Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-07-01 | 2026-08-03 |
| Safety, Tolerability, and Efficacy of Oral KM-023 in Adult Patients With Pachyonychia Congenita (pEDD-PC) KM-023 - Pachyonychia Congenita | Phase 2 | Not yet recruiting | Orvida Pharma (formerly Kamari Pharma) | 10 | 2026-12-01 | 2026-10-26 |
| Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal Dysplasia ER004 - X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) | Phase 2 | Recruiting | EspeRare Foundation | 20 | 2022-04-26 | 2025-04-30 |
| Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita PTX-022, Placebo - Pachyonychia Congenita | Phase 2 / Phase 3 | Completed | Palvella Therapeutics, Inc. | 73 | 2019-04-01 | 2024-08-29 |
| Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) EDI200 - X-Linked Hypohidrotic Ectodermal Dysplasia | Phase 2 | Completed | Edimer Pharmaceuticals | 6 | 2013-04-01 | 2016-01-20 |
Pachyonychia Congenita (3) · Ectodermal Dysplasia 1, Anhidrotic (2) · Hyperkeratosis, Epidermolytic (1) · Keratoderma, Palmoplantar (1)
Abnormalities, Multiple (5) · Congenital Abnormalities (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Skin Abnormalities (5) · Skin Diseases (5) · Skin Diseases, Genetic (5) · Skin and Connective Tissue Diseases (5) · Nail Diseases (3) · Genetic Diseases, X-Linked (2) · Ichthyosiform Erythroderma, Congenital (1) · Ichthyosis (1) · Infant, Newborn, Diseases (1) · Keratosis (1)
3-(3-ethyl-5-isopropyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carbonyl)-5-methylbenzonitrile (1) · Erlotinib Hydrochloride (1) · Fc-EDA (1)
Edimer Pharmaceuticals (1) · EspeRare Foundation (1) · Northwestern University (1) · Orvida Pharma (formerly Kamari Pharma) (1) · Palvella Therapeutics, Inc. (1)
United States (4) · France (2) · Germany (2) · Italy (2) · United Kingdom (2) · Israel (1) · Spain (1)
Amy Paller (1) · David Hansen, MD (1) · Holm Schneider, MD (1) · Joyce Teng, MD (1) · Kenneth Huttner, MD, PhD (1)